UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, D.C. 20549


                                   FORM 10 QSB

            Quarterly Report Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


            For the quarterly period ended           December 31, 2000

            Commission file Number                   000-25019


                                 PVAXX CORPORATION
                       (Formerly Oak Brook Capital IV, Inc.)

              (Exact Name of Registrant as Specified in its Charter)


                                     COLORADO
                  (State or Other Jurisdiction of Incorporation)



               000-25019                                05-0499528
        (Commission File Number)         (I.R.S. Employer Identification Number)



      12730 New Brittany Boulevard
           Fort Myers, Florida                            33907
(Address of Principal Executive Offices)               (Zip Code)



                                 (941) 274-9355
              (Registrant's Telephone Number, Including Area Code)


<PAGE>

Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                         YES [X]        NO [  ]

Indicate the number of shares outstanding of each of the
issuer's classes of common stock, as of the latest practical
date:

Common Stock, No Par Value - 21,322,800 shares as of
December 31, 2000.


<PAGE>  1

                           FORWARD-LOOKING INFORMATION

THIS FORM 10QSB AND OTHER STATEMENTS ISSUED OR MADE FROM TIME TO TIME BY
PVAXX CORPORATION INCORPORATED OR ITS REPRESENTATIVES CONTAIN STATEMENTS
WHICH MAY CONSTITUTE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF
THE SECURITIES ACT OF 1933 AND THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED BY THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FIFTEEN
U.S.C.A. SECTIONS 77Z-2 AND 78U-5 (SUPP. 1996). THOSE STATEMENTS INCLUDE
STATEMENTS REGARDING THE INTENT, BELIEF OR CURRENT EXPECTATIONS OF PVAXX
CORPORATION AND MEMBERS OF ITS MANAGEMENT TEAM AS WELL AS THE ASSUMPTIONS
ON WHICH SUCH STATEMENTS ARE BASED.

PROSPECTIVE INVESTORS ARE CAUTIONED THAT ANY SUCH FORWARD-LOOKING STATEMENTS
ARE NOT GUARANTEES OF FUTURE PERFORMANCE AND INVOLVE RISKS AND UNCERTAINTIES,
AND THAT ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY SUCH
FORWARD-LOOKING STATEMENTS. IMPORTANT FACTORS CURRENTLY KNOWN TO MANAGEMENT
THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN FORWARD-
LOOKING STATEMENTS ARE SET FORTH IN THE SAFE HARBOR COMPLIANCE STATEMENT FOR
FORWARD-LOOKING STATEMENTS INCLUDED AS EXHIBIT 99.1 TO THIS FORM 10QSB AND
ARE HEREBY INCORPORATED HEREIN BY REFERENCE. THE COMPANY UNDERTAKES
NO OBLIGATION TO UPDATE OR REVISE FORWARD-LOOKING STATEMENTS TO REFLECT
CHANGED ASSUMPTIONS, THE OCCURRENCE OF UNANTICIPATED EVENTS OR CHANGES TO
FUTURE OPERATING RESULTS OVER TIME.


ITEM 1.  FINANCIAL STATEMENTS

<PAGE>  F-1

                                PVAXX CORPORATION
                         (FORMERLY OAKBROOK CAPITAL IV)
                                 & SUBSIDIARIES
                          (Development Stage Companies)
                        CONSOLIDATED FINANCIAL STATEMENTS
                               December 31, 2000
                                   (Unaudited)

The following financial statements include a consolidated balance sheet as of
December 31, 2000, consolidated statements of operations and deficit
accumulated during development stage, consolidated statements of changes in
stockholders' equity and consolidated statements of cash flows for the three
and six months ended December 31, 2000 and 1999 respectively, and for the
period from May 1, 1998 (inception) through December 31, 2000.


                        PVAXX CORPORATION & SUBSIDIARIES



Index to Financial Statements                                  1
Accountant's Review Report                                     2
Consolidated Balance Sheet                                     3
Consolidated Statements of Operations & Deficit Accumulated
 During Development Stage                                      4
Consolidated Statements of Changes in Stockholders' Equity     5
Consolidated Statements of Cash Flows                          6
Notes to Financial Statements                                  7


<PAGE>  F-2

                           BERSCH ACCOUNTING S.C.
                        Certified Public Accountants

633 W. Wisconsin Ave., Suite 405                   Milwaukee, Wisconsin 53203
Tel: 414-272-8800                                    www.berschaccounting.com
Fax: 414-223-4070                                    email: bersch@execpc.com

February 17, 2001

Shareholders and Board of Directors
PVAXX CORPORATION
Fort Myers, Florida

Accountant's Review Report


I have reviewed the accompanying consolidated balance sheet of PVAXX
Corporation and Subsidiaries as of December 31, 2000 and the related
consolidated statements of operations & deficit accumulated during the
development stage, changes in stockholders' equity and cash flows for the
three and six months then ended and from May 1, 1998 (inception) through
December 31, 2000, in accordance with Statements of Standards for Accounting
and Review Services issued by the American Institute of Certified Public
Accountants.  All information included in these financial statements is the
representation of the management of PVAXX Corporation and Subsidiaries.

A review consists principally of inquiries of company personnel and analytical
procedures applied to financial data.  It is substantially less in scope than
an audit in accordance with generally accepted auditing standards, the
objective of which is the expression of an opinion regarding the financial
statements taken as a whole.  Accordingly, I do not express such an opinion.

On the basis of my review, I am not aware of any material modifications that
should be made to the accompanying consolidated financial statements in order
for them to be in conformity with generally accepted accounting principles.


Dennis W. Bersch, CPA
Milwaukee, WI

<PAGE>  F-3

                            PVAXX CORPORATION
                     (FORMERLY OAK BROOK CAPITAL IV)
                              & SUBSIDIARIES
         (With Accountant's Review Report of February 17, 2001)
                        CONSOLIDATED BALANCE SHEET
                               (UNAUDITED)

<TABLE>
<CAPTION>
                                  ASSETS

<S>                                                <C>           <C>           <C>


CURRENT ASSETS:
     Cash and cash equivalents                     $     8,360
     Restricted cash and cash equivalents (Note 6)     299,970
     VAT tax refund receivable                          22,745
            Total current assets                                 $   406,336
FIXED ASSETS
     Machinery & equipment                         $   589,497
     Office equipment                                   19,847
     Furniture & fixtures                               67,994
     Motor vehicles                                     50,779
     Less:  accumulated depreciation                  (136,987)
            Net fixed assets                                         591,130
 OTHER ASSETS:
     Prepaid expenses                              $    16,192
     Deposits                                            4,349
     Patent rights (Note 1)                             66,400
            Total other assets                                        86,940

            Total assets                                                       $ 1,084,406


                   LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:
     Accounts Payable                              $   122,627
     Current portion of
      long-term liabilities (Note 10)                    2,860
     Accrued wages - officers                          499,935
     Accrued interest - loans payable to
      officers/directors (Note 3)                      133,574
     Other accrued liabilities                          31,292
          Total current liabilities                              $   790,288
LONG TERM LIABILITIES:
     Notes payable (Note 10)                       $     3,089
     Capital lease to related parties (Note 10)        635,130
     Loans payable to officers/directors (Note 3)      971,728
          Total long term liabilities                              1,609,946

          Total liabilities                                                    $ 2,400,235

SHAREHOLDERS' EQUITY (DEFICIT):
     Preferred stock - no par value, 0%,
      noncumulative, nonparticipating, convertible
      10,000,000 shares authorized,
      issued and outstanding (Note 1)                            $   100,000
     Common stock - no par value,
      40,000,000 shares authorized
      21,322,800 shares issued and outstanding
      of which 90,000 shares are in escrow (Note 6)                  204,200
     Paid in Capital                                                 217,914
     Accumulated other comprehensive income                           12,382
     Deficit accumulated during the development stage             (1,850,325)

          Total equity                                                          (1,315,829)

          Total liabilities and equity                                         $ 1,084,405

</TABLE>

<PAGE> F-4

                 PVAXX CORPORATION (FORMERLY OAKBROOK IV) & SUBSIDIARIES

                               (Development Stage Companies)
                 (With Accountant's Review Report of February 17, 2001)

         CONSOLIDATED STATEMENT OF OPERATIONS AND DEFICIT ACCUMULATED DURING
                                    DEVELOPMENT STAGE
          For the three and six months ended December 31, 2000 and 1999 and
                from May 1, 1998 (Inception) thru December 31, 2000
                                       (Unaudited)

<TABLE>
<CAPTION>

                                (Unaudited)    (Unaudited)    (Unaudited)    (Unaudited)    (Unaudited)
                                     December 31, 2000             December 31, 1999      Since Inception

                                 3 months       6 months       3 months       6 months

<S>                             <C>            <C>            <C>            <C>            <C>

REVENUE                         $      2,403   $      2,442   $          -   $          -   $      2,442

COST OF REVENUE
   Direct costs                           57             58              -              -             58
                                ------------   ------------   ------------   ------------   ------------

      Gross profit              $      2,346   $      2,385   $          -   $          -   $      2,385

OPERATING EXPENSES
   Development costs            $    308,290   $    366,275                                 $    406,296
   Finance costs                           -              -                                       26,962
   Administrative costs              533,273        961,910              -              -   $  1,352,236
                                ------------   ------------   ------------   ------------   ------------

      Total operating expenses       841,564      1,328,185              -              -      1,785,494

      Operating income (loss)   $   (839,217)  $ (1,325,800)  $          -   $          -   $ (1,783,109)

OTHER INCOME AND (EXPENSES)          (54,130)       (55,031)             -              -        (67,216)
                                ------------   ------------   ------------   ------------   ------------

Net Operating Income (Loss)     $   (893,348)  $ (1,380,831)  $          -   $          -   $ (1,850,325)

INCOME TAXES                               -              -              -              -              -
                                ------------   ------------   ------------   ------------   ------------

Net loss and Deficit
 accumulated during the
 development stage              $   (893,348)  $ (1,380,831)  $          -   $          -   $ (1,850,325)
                                ------------   ------------   ------------   ------------   ------------

PER SHARE INFORMATION
  Weighted average number of
  common shares outstanding       21,322,800     21,322,800                                   21,070,078

      Profit (loss) per share   $      (0.04)  $      (0.06)                                $      (0.09)
                                ------------   ------------   ------------   ------------   ------------

  Fully diluted shares            31,322,800     31,322,800                                   31,070,078

    Profit (loss) per
     fully diluted share        $      (0.03)  $      (0.04)                                $      (0.06)

</TABLE>

     The accompanying notes are an integral part of these financial statements.


<PAGE> F-5

               PVAXX CORPORATION (Formerly Oakbrook IV) AND SUBSIDIARIES
                              (Development Stage Companies)
                (With Accountant's Review Report of February 17, 2001)
                     STATEMENT OF CHANGES IN STOCKHOLDERS EQUITY
                      From inception through December 31, 2000
                                       (Unaudited)

<TABLE>
<CAPTION>
                              Shares Issued
                              ------------------------------
                                                                                              Accumulated
                              Common     Preferred   Common      Preferred                    Comprehensive  Retained
                              Stock      Stock       Stock       Stock       Paid-in-Capital  Income         Earnings   Equity
                              ---------- ----------- ----------- ----------- ---------------  -------------  ---------- ----------
<S>                           <C>        <C>         <C>         <C>         <C>              <C>            <C>        <C>
Acquisition of subsidiary
corporations by PVAXX Corp

 Issuance of common stock
 for subsidiary companies
 3/31/00                      19,865,168             $   198,652 $           $    (237,728)   $           -  $        - $  (39,076)

 Issuance of common stock
 for cash
 3/31/00                          44,832                     448                   156,572                                 157,020

 Issuance of common stock for
 cash restricted by investor
 3/31/00                          90,000                     900                   299,070                                 299,970

 Issuance of preferred stock
 3/31/00                                  10,000,000                  100,000                                              100,000

Reverse merger with Oak Brook
IV
 Net assets of Oak Brook IV
 IV 5/19/00                    1,322,800                   4,200                                                (10,225)    (6,025)

Foreign currency
translation adjustment                                                                                8,882                  8,882

Net loss for the period
ended 6/30/00                          -           -           -            -                -            -    (459,269)  (459,269)
                              ----------  ----------  ----------  -----------     ------------  -----------   ----------  ---------

Balance 6/30/2000             21,322,800  10,000,000  $  204,200  $   100,000     $    217,914  $     8,882   $(469,494) $  61,502

Foreign currency translation
adjustment                                                                                            3,500                  3,500

Net loss for the period
ended 12/31/00                         -           -           -            -                -            -  (1,380,831)(1,380,831)
                              ----------  ----------  ----------  -----------     ------------ ------------  ----------  ---------

Balance 12/31/2000            21,322,800  10,000,000  $  204,200  $   100,000     $    217,914  $    12,382 $(1,850,325)(1,315,829)
                              ----------  ----------  ----------  -----------     ------------ ------------  ----------  ---------

</TABLE>

     The accompanying notes are an integral part of these financial statements.

<PAGE> F-6

          PVAXX CORPORATION (FORMERLY OAKBROOK IV) & SUBSIDIARIES
                       (Development Stage Companies)
          (With Accountant's Review Report of February 17, 2001)

                    CONSOLIDATED STATEMENT OF CASH FLOWS
       For the three and six months ended December 31, 2000 and 1999
          and from May 1, 1998 (Inception) thru December 31, 2000
                                 (Unaudited)

<TABLE>
<CAPTION>
                                                        (Unaudited)    (Unaudited)    (Unaudited)    (Unaudited)    (Unaudited)

                                                             December 31, 2000            December 31, 1999         Since Inception
                                                        3 months       6 months       3 months       6 months

<S>                                                     <C>            <C>            <C>            <C>            <C>

CASH FLOWS FROM OPERATING ACTIVITIES:
  Net Loss                                              $    (893,348) $ (1,380,831)  $          -   $           -  $ (1,850,325)
  Adjustments to reconcile net loss to net cash
   provided by (used in) operating activities:
    Depreciation & amortization                         $      30,043       118,050                                 $    137,847
    Decrease (Increase) in VAT taxes receivable                14,520          (144)                                     (22,890)
    (Increase) in inventories                                 (74,522)      (75,752)                                     (75,742)
    Increase (Decrease) in prepaid expenses                    15,000        15,000                                      (16,295)
    (Increase) in security deposits                                                                                       (4,349)
    Foreign currency adjustments                                             (4,864)
    (Decrease) Increase in accounts payable                    12,593        (1,253)                                     123,289
    Increase in accrued interest                              123,232       125,231                                      134,361
    (Decrease) Increase in accrued liabilities                 (4,237)        8,239                                       31,402
    Increase in accrued officer wages                         169,935       319,935              -               -       499,935
                                                        -------------- -------------  ------------   -------------  -------------
 Net cash provided by (used in) operating activities    $    (606,782) $   (876,379)  $          -   $           -  $ (1,042,768)

CASH FLOWS FROM INVESTING ACTIVITIES:
    Purchase/investment of intangible patent                   (2,758)       (2,803)                                     (66,824)
    Purchase of equipment and improvements                    (28,445)      (36,300)             -               -       (93,486)
                                                        -------------- -------------  ------------   -------------  -------------
 Net cash provided by (used in) investing activities    $     (31,203) $    (39,103)  $          -   $           -  $   (160,310)

CASH FLOWS FROM FINANCING ACTIVITIES:
    Proceeds from notes & loans payable                 $           -  $          -   $          -   $           -  $      7,504
    Increase in loans to Officers/Directors                    620,972      806,250                                      977,600
    Proceeds from notes & loans payable -
     related parties
    Repayments of notes & loans payable                         (1,019)      (1,036)                                      (1,517)
    Proceeds from sale of common stock                                                                                   417,914
    Proceeds from sale of preferred stock                                                                                100,000
    Sale of common stock for services                                                                                      4,200
    Cash restricted by investor                                      -            -              -               -      (299,970)
                                                        -------------- ------------   ------------   -------------  -------------
 Net cash provided by (used in) financing activities           619,953      805,250              -               -     1,205,731
                                                        -------------- ------------   ------------   -------------  -------------

EFFECT OF EXCHANGE RATE CHANGES ON CASH                            146           55              -               -         5,707
                                                        -------------- ------------   ------------   -------------  -------------

(Decrease) Increase in Cash and Cash Equivalents               (17,887)    (110,213)             -               -         8,360

Cash at beginning of period                                     26,247      118,573              -               -             -
                                                        -------------- ------------   ------------   -------------  -------------

Cash at end of period                                   $        8,360 $      8,360   $          -   $           -  $      8,360
                                                        -------------- ------------   ------------   -------------  -------------
Supplemental information:
    Interest paid                                       $          903 $        903   $          -   $           -  $     16,790
    Income tax expense                                               -            -              -               -             -

Noncash transactions
  Purchase of machinery in exchange for
  related party lease
    Machinery & Equipment                               $      639,187
    Capital Lease with related party                          (639,187)
                                                        --------------

                                                        $            -
                                                        ==============
</TABLE>

     The accompanying notes are an integral part of these financial statements.

<PAGE>  F-7

      PVAXX CORPORATION (FORMERLY OAKBROOK CAPITAL IV) & SUBSIDIARIES

                       NOTES TO FINANCIAL STATEMENTS
                          AS OF DECEMBER 31, 2000


NOTE 1 - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

HISTORY OF THE REPORTING ENTITY
PVAXX  Corporation, formed in Florida in 2000, is the parent corporation of
PVAXX  Research   &   Development  LTD,  PVAXX,  (Europe)  LTD,  and  PVAXX
Technologies LTD.  PVAXX  Corporation purchased net business assets at fair
value of PVAXX Research & Development  LTD  and  PVAXX  Technologies LTD in
exchange  for 10,000,000 shares of its Preferred and 20,000,000  shares  of
its Common  stock.   The  net  business  assets  consisted  of  two  patent
applications  described  below,  current  liabilities, and a vehicle.  This
transaction was accounted for as a combination  of  entities  under  common
control.   The  PVAXX  companies were owned and controlled by the acquiring
Company's President and  Chairman of the Board of Directors, Henry Stevens.
The only activities of any of these companies to date have been development
stage activities.

 The role of each of the subsidiary companies is as follows:

-    PVAXX  Technologies,  Ltd.  is  the  holder  of  unlimited  rights  to
     manufacture, process, and sell poly vinyl alcohol products governed by
     patents issued under International  Publication Numbers WO 98/26911 on
     June 25, 1998 and WO 00/12615 on March 9, 2000

-    PVAXX  Research and Development Ltd. performs  research  into  product
     improvements  and  applications.  Doing business as PVAXX Engineering,
     it produces machines  forming the product into pellets, which are then
     sold to converters.  Under  the trade  style PVAXX SoftCap Systems it
     manufactures and sells capsule making machinery

-    PVAXX Europe Ltd. is a dormant company.

Oakbrook Capital IV, (Oakbrook IV) was formed in May 1998 in Colorado, with
40,000,000  shares  of  common  and 10,000,000 shares  of  preferred  stock
authorized.  It was registered with  the  SEC  as  one of a series of blank
check companies seeking a business combination with  an  operating company.
On May 19, 2000, Oakbrook IV entered into a share exchange  agreement, with
PVAXX Corporation, a development stage company. The transaction is reported
herein as a reverse acquisition with PVAXX as the accounting  acquirer  and
Oak Brook IV as the legal survivor.

In  conjunction  with  the reverse acquisition, Oakbrook IV, changed its name to
PVAXX Corporation, and the  newly  named  PVAXX and all of the subsidiaries
have changed their respective fiscal year-ends to June 30.

PRINCIPLES OF CONSOLIDATION
These financial statements include the combined  accounts  of  the Colorado
corporation,  Oak  Brook  Capital  IV,  and the former Florida corporation,
PVAXX Corporation.  They are consolidated  with  the  three  100%  owned  UK

<PAGE> F-8

subsidiary   corporations  (PVAXX  Technologies,  Ltd.,  PVAXX  Research  &
Development, Ltd. and PVAXX Europe, Ltd.).  After conversion of UK currency
to US dollars, all significant inter-company accounts and transactions have
been eliminated.

FOREIGN CURRENCY TRANSLATION AND TRANSACTIONS
The financial  position  and results of operations of the company's foreign
subsidiaries are determined  using  the  local  currency  as the functional
currency.  Assets and liabilities of these subsidiaries are  translated  at
the exchange rate in effect as of the balance sheet date.  Income statement
accounts  are  translated at the average rate of exchange prevailing during
the period. Translation  adjustments  arising  from  the  use  of differing
exchange rates from period to period are included in the accumulated  other
comprehensive income account in shareholder's equity section.

USE OF ESTIMATES
The  process of preparing financial statements in conformity with generally
accepted  accounting  principles  requires management to make estimates and
assumptions that affect the reporting  of amounts of assets and liabilities
and disclosure of contingent assets and  liabilities  at  the  date  of the
financial  statements  and  the  reported  amounts of revenues and expenses
during the reporting period.

CASH AND CASH EQUIVALENTS
Highly liquid assets with a maturity date of  three (3) months or less from
the date of acquisition are treated as cash or cash equivalents.

PROPERTY AND EQUIPMENT
Property  and  equipment  is stated at cost less accumulated  depreciation.
Depreciation is computed using  straight-line  and accelerated methods over
estimated useful lives of the property.  Estimated useful lives of property
& equipment are as follows:

              Machinery & equipment        3 to 15 years
              Office equipment             5 years
              Furniture & fixtures         5 to 7 years
              Motor vehicles               5 years

The amortization of leasehold improvements is based  on  the shorter of the
lease term or the life of the improvement.

Betterments  and  large  renewals, which extend the life of an  asset,  are
capitalized whereas maintenance and repairs and small renewals are expensed
as incurred.

Inventory
Inventories consist of raw materials and are stated at the lower of cost
(first-in, first-out) or net realizable value.

<PAGE>  F-9

VAT TAXES RECEIVABLE
The United Kingdom subsidiaries are required to pay a Value Added Tax (VAT)
on purchases made from certain  vendors.  The company receives a tax refund
for the VAT paid to various vendors.

OTHER ACCRUED LIABILITIES
Other accrued consist of accrued  employee wages, and payroll taxes, due as of
the balance sheet date.

INTANGIBLES
The patents were acquired from a related party in exchange for stock in the
PVAXX group of companies.  The fair  of  the patents was deemed to be their
historical cost at the date of acquisition  and the stock was valued at the
historical cost of the patent.  Intangible assets  such as patents on other
intellectual  property are recorded at cost if it is  determinable  at  the
date of acquisition.   Such  intangible assets are amortized over estimated
useful lives based on the nature  of  the  item.   The  Company  will begin
amortizing its patent when it emerges from the development stage.

In  accordance  with  SFAS  121,  "Accounting  for Impairment of Long-Lived
Assets and Long-Lives Assets to be Disposed of",  intangibles are evaluated
for impairment when events or changes in circumstances  indicate  that  the
carrying amounts of the assets may not be recoverable through the estimated
undiscounted  future  cash  flows  resulting  from the use of these assets.
When any such impairment exists, the related assets  are  written  down  to
fair value.

The  company  has  not generated any revenue relating to its patents due to
the fact that its operations  are in the development stage.  Although there
is substantial doubt about the  company's  ability  to  continue as a going
concern as described in Note #9, the company has just acquired  the patents
and it is actively engaged in promoting and developing this technology.  At
this  time  there are no events and conditions that exist to indicate  that
the  asset maybe  impaired.  However, should the company's efforts to
negotiate long-term revenue contracts for its products be unsuccessful, the
company may realize an impairment loss on the write-down of the patent to
its fair value.


INCOME TAXES
The Company uses the asset and liability method as identified  in SFAS 109,
Accounting for Income Taxes.

The  consolidated  Company  has a net operating loss carryforward (NOL)  of
$1,850,325 available to future  periods  due  to  losses  generated since its
inception  through  December 31, 2000.  The net operating losses  and  credits
expire at various dates beginning  in  2018  and  continuing  through 2020.
This NOL would result in a tax debit based on application of appropriate UK
and  US  tax  rates  if  offsetting profits were anticipated.  Because  the
Company and its subsidiaries  are  in  the  development stages, there is no
assurance  that  future  operations  will  generate  a  profit  or  income,
therefore the company recognizes a valuation  adjustment  which  completely
offsets   the  deferred  tax  asset  related  to  the  net  operating  loss
carryforward.

<PAGE>  F-10

STOCK EXCHANGED FOR SERVICES
The issuance  of  equity  instruments in exchange for goods or services are
accounted for based upon the  fair value of the goods or services received.
The services exchanged for equity  shown  on  the  statements of changes of
stockholder's equity were valued at $.003/share because  it  was determined
that  $4,200  worth of legal services had been provided to set up  the  Oak
Brook IV shell.

CONVERTIBLE PREFERRED STOCK
The Company issued  convertible preferred stock relating to the transaction
discussed above and in  Note  3.   The preferred stock does not have voting
rights, and is noncumulative, nonparticipating and has preference up to its
par value upon liquidation.  The stock  may be  converted 1 for 1 for common
stock.

NOTE 2 -  ACCOUNTS RECEIVABLE

Management believes all receivables are due and  collectible and no reserve
for un-collectable amounts is necessary.

NOTE 3 -  RELATED PARTY TRANSACTIONS

Through  a  series  of transactions, the Company effectively  acquired  the
PVAXX Business Group  from a company owned and controlled by Henry Stevens,
the  present  majority  owner   of   PVAXX   Corporation.    The   ultimate
consideration  for  the  transaction  is the 10,000,000 shares of Preferred
stock  and 20,000,000 shares of Common stock  held  by  Henry  Stevens  and
others whose  PVAXX  Florida  corporation shares were exchanged.  The PVAXX
Business Group consists of the subsidiary companies described in Note 1.

The President, and another officer,  advanced $971,728 to the Company.  The
amounts  advanced  are  due upon demand and  the  effective  interest  rate
assumed is 8%.  The company  has  accrued  $124,557 of  interest relating to
these advances.

The patent rights owned by PVAXX Technologies, Ltd., were  developed by and
acquired  from  a  company owned by the President, Henry Stevens,  and  are
carried at their actual  cost  of  $66,400  after  adjustment  for  foreign
currency.

The Company entered into an Employment Agreement dated March 20, 2000  with
Henry  Stevens,  the  Company's  President  and  Chairman  of  the Board of
Directors. The Agreement is for a term of five years and renewable  by  the
Company.


Under the Agreement, the Company agrees to pay the following amounts:

                         a)   $50,000 per month net of all taxes;

                         b)   Use  of  a motor vehicle at the choice of the
                              employee;

                         c)   Use of residential  facilities  in  the  Fort
                              Myers  area at a rental not to exceed $36,000
                              per annum; and

                         d)   The  Company  will  establish  a  performance
                              related share option program, under which the
                              company's  board  of directors will determine
                              participation    commensurate     with    the
                              employee's position.  However, as of  balance
                              sheet  date,  the  Company has not officially
                              established a share option plan.

<PAGE>  F-11

No  payments  have been made under the Agreement as  of  the  date  of  the
financial statements.

NOTE 4 -  RISKS AND UNCERTAINTIES

The Company's future  operating  results  may  be  affected  by a number of
factors.  The  ability  of  the  Company to raise the capital necessary  to
continue to develop and bring its  products  to market is not assured.  The
product  being  developed by PVAXX will be sold  in  a  highly  competitive
global  market  in   which   it   will   need  to  demonstrate  performance
characteristics  sought by customers, at a  competitive  price  which  will
yield a profit after  production  and distribution costs.  Estimates of the
size of the market, and the company's  eventual  market  share  may  not be
realized, and the effect of competition cannot be determined.

NOTE 5 -  COMMITMENTS AND CONTINGENT LIABILITIES

LEASED FACILITIES - OPERATING LEASE
The  Company  has  entered into a three (3) year operating lease for office
space in the Fort Myers  area  with an unrelated party.  Under the terms of
this lease, effective June 1, 2000  the  Company  is  obligated for monthly
base  rental  amounts  plus  sales  tax  and Common Area Maintenance  (CAM)
charges. Under the terms of the lease, the Company is obligated to keep and
maintain the leased premises, including fixtures  and improvements, in good
condition.

The  Company is obligated for the following rent payments  over  the  lease
term:

<TABLE>
<CAPTION>
                   Total     Monthly             Sales
                   Rent      Base Rent   CAM     Tax
<S>                <C>       <C>         <C>     <C>
Year 1
     1st quarter  $11,013    $2,000      $1,463  $208
     2nd quarter   11,013     2,000       1,463   208
     3rd quarter   12,285     2,400       1,463   232
     4th quarter   13,239     2,700       1,463   250

Year 2             55,080     2,808       1,522   260

Year 3             57,276     2,920       1,583   270
</TABLE>

EMPLOYEE COMPENSATION
In addition to the employment contract with the President disclosed in Note
3,  an arrangement with the Vice-president provides for a salary of $10,000
monthly for one year, and $15,000 thereafter.

NOTE 6 -  RESTRICTED CASH

On March  3, 2000, the former PVAXX executed an agreement with an unrelated
individual  who  transferred  $299,970 to an escrow agent in exchange for a
90,000 share block of the 20,000,000  shares  of  common  stock  issued  as
discussed  in  Notes  1  and  3.   Under the terms of the escrow agreement,
updated and signed on August 4, 2000,  the  funds  will  be released to the
company when the exchanged shares of the new PVAXX Corporation are tradable
on a U.S. national exchange at not less than $5.00 per share.   If  this is
not  achieved,  the  funds  may  be released to

<PAGE>  F-12

the investor six (6) months
after the effective date (August 4,  2000) of the agreement, upon return of
the 90,000 shares which would then be  held  in the treasury for resale. The
company has arranged a ninety day extension of this agreement.  As of balance
sheet date the 90,000 shares of stock  as  well  as the $299,970 remain in
the custody of the escrow agent.

NOTE 7 -  FAIR VALUES OF FINANCIAL INSTRUMENTS

The  carrying amounts reported in the consolidated balance sheet  for  cash
and cash  equivalents,  restricted  cash,  receivables,  accounts  payable,
accrued  expenses and other liabilities, approximate fair value because  of
immediate  or  short-term  maturity  of  these  financial instruments.  The
underlying carrying amount reported for long-term  debt  and capital leases
approximates fair value because, in general, the interest on the underlying
instruments fluctuates with market rates.

NOTE 8 -  EARNINGS PER SHARE

Basic  earnings  per share are computed by dividing earnings  available  to
common stockholders  by  the  weighted  average  number  of  common  shares
outstanding  during  the  period.   Diluted  earnings per share reflect per
share  amounts that would have resulted if all  preferred  stock  had  been
converted  to common stock.  The following reflects amounts reported in the
financial statements:


<PAGE>  F-13

<TABLE>
<CAPTION>
                                                       For the 3 months ended December 31, 2000
                                            --------------------------------------------------------
                                            Income             Shares               Per-share
                                            (Numerator)        (Denominator)        Amount
<S>                                         <C>                <C>                  <C>
Income available to common stockholders
   -basic earnings per share                $  (893,348)        21,322,800          $    (0.04)
Effect of dilutive securities
   -convertible preferred stock                                 10,000,000
                                            --------------------------------
Income available to common stockholders
   -fully diluted earnings per share        $  (893,348)        31,322,800          $    (0.03)
                                            ========================================================


                                                       For the 6 months ended December 31, 2000
                                            --------------------------------------------------------
                                            Income             Shares               Per Share
                                            (Numerator)        (Denominator)        Amount

Income available to common stockholders
   -basic earnings per share                $(1,380,831)        21,322,800          $    (0.06)
Effect of dilutive securities
   -convertible preferred stock                                 10,000,000
                                            --------------------------------
Income available to common stockholders
   -fully diluted earnings per share        $(1,380,831)        31,322,800          $    (0.04)
                                            ========================================================

                                               For the 3 months ended December 31, 1999

Income available to common stockholders     $         -                             $        -
                                            ========================================================
   -basic earnings per share


                                               For the 6 months ended December 31, 1999

Income available to common stockholders     $         -                             $        -
                                            ========================================================
   -basic earnings per share


                                                               From inception
                                            --------------------------------------------------------
Income available to common stockholders
   -basic earnings per share                $(1,850,325)         21,070,078         $    (0.09)
Effect of dilutive securities
   -convertible preferred stock                                  10,000,000
                                            -------------------------------
Income available to common stockholders
   -fully diluted earnings per share        $(1,850,325)         31,070,078         $    (0.06)
                                            -------------------------------------------------------
</TABLE>

NOTE 9 - GOING CONCERN CONSIDERATIONS

The ability  of  the  Company  to  emerge from the development stage and to
develop into a going concern is dependent  on the success of the Company in
negotiating  long-term revenue contracts and  acquiring  additional  equity
capital.  However,  there  can  be  no  assurance  that the Company will be
successful  in accomplishing its objectives.  The financial  statements  do
not include any

<PAGE>  F-14

adjustments that might be necessary should the company, be
unable to continue as a going concern.

The company is addressing  the  substantial  doubt  about  its  ability  to
continue  as  a  going concern through the deferral of cash payments to the
principal shareholders,  through  the  negotiation  of  anticipated private
placements  with  additional  investors,  and by taking steps  to  register
shares  for  sale  on  the public market in order  to  generate  additional
working capital, in order  for  the company to expand its operations and to
bring it's product to the market.   In  addition,  certain of the company's
officers and shareholders have agreed that they will advance to the company
some  additional  funds  that  the  company  needs  for operating  capital.
Although, as of the balance sheet date of December 31,  2000,  the Company
had  not  entered  into any revenue-producing contracts, several successful
field tests of various products have been conducted by potential customers,
and management expects to have successfully  negotiated  several  contracts
before the end of this fiscal year.  Furthermore, as discussed in Note #3 the
Company's majority shareholder has advanced the Company $971,728 thus
enabling the Company to continue operating and, as discussed in Note #10,
Jumik Investments, Inc. has agreed to accept a deferred payment arrangement
further facilitating the ongoing operations and bringing to market of the
Company's products.

NOTE 10 - LONG TERM LIABILITIES AND CAPITAL LEASES

Long-term liabilities include a three-year capital  lease dated May 1, 2000
with Jumik Investments, a company owned and controlled  by  Henry  Stevens,
the  present  majority  shareholder  of  PVAXX  Corporation, for equipment,
office furniture and vehicles.  The terms of the  lease require the company
to pay $12,534 per month as adjusted for foreign currency, interest of 2.5%
plus a balloon payment for the balance at the end of  the term.  At the end
of  the  term,  PVAXX will own the leased assets.  The fair  value  of  the
leased assets were determined to be 50% of Jumik's original cost due to the
fact that they have been previously used by the lessor.  The lease does not
require the company to restrict its, dividends, additional debt, or further
leasing.  These lease  terms have been deemed to be comparable with similar
arrangements with unrelated parties.  However, to facilitate working capital
needs of the Company, Jumik Investments, Inc. has agreed to suspend payments
on this lease until the company either successfully acquires additional
equity financing, or has secured several long-term revenue producing
contracts, thus providing the capital necessary to meet this commitment.
Interest will continue on this contract at the rate discussed above. As of
balance sheet date, the Company has accrued interest of $9,017 relating
to this lease.

The automobile note is with  an  unrelated  party. Depreciation expense for
leased assets is included in depreciation expense for owned assets.

The gross amounts of assets recorded under capital leases are listed in the
table below at currency rates in effect:

<PAGE> F-15


                 Machinery & equipment            $586,807
                 Furniture & fixtures               44,730
                 Motor vehicles                     50,779
                                                  --------

                 Total leased assets acquired      682,316

                 Less accumulated depreciation    (130,038)
                                                  --------

                 Net leased assets                $552,278
                                                  --------

The  future  minimum  lease  payments  and  the  obligations  owed  on  the
automobile note are listed in the table below.

<TABLE>
<CAPTION>

                          Capital Lease      Auto Note
      <S>                 <C>                <C>
      2001                                   $  2,860
      2002                                      3,088
      2003                   635,130                -
                          ----------         --------

      Current                                $  2,860
      Longterm               635,130            3,088
                          ----------         --------

      Total               $  635,130         $  5,948
                          ----------         --------
</TABLE>

PVAXX CORPORATION IS THE GUARANTOR OF THESE LEASES.

<PAGE> 2

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR
         PLAN OF OPERATION

                                PVAXX CORPORATION

                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS


                                December 31, 2000

                     ======================================
                      SIX MONTHS ENDING DECEMBER 31, 2000
                     ======================================

Except for historical information, the discussion in this Form 10-QSB contains
forward-looking statements that involve risks and uncertainties. These
statements may refer to the Company's future plans, objectives, expectations
and intentions. These statements may be identified by the use of words such
as "expect", "anticipate", "believe", "intend", "plan" and similar expressions.

The Company's actual results could differ materially from those anticipated
in such forward-looking statements. Factors that could contribute to these
differences include, but are not limited to, the risks discussed in the
section titled "Market Risks and other Business Factors" later in this
Form 10-QSB.

Plan of Operation

The Company is producing PVAXX(R), that may be used by various manufacturers
in producing agricultural, pharmaceutical, adhesives and food market products.
The Company and its Chairman have spent the past several years developing
PVAXX(R) and related technology and the Company is now selling limited
quantities of PVAXX(R) for evaluation by potential customers operating in the
following industries:

-Pharmaceutical;
-Industrial;
-Retail;
-Household;
-Agricultural;
-Leisure.

Year 2000

The Company has accomplished the following during the calendar year 2000:

-has opened new facility and European HQ in Kemble
-is presently supplying pre-production samples to potential customers;
-has commenced a public relations program;
-has appointed several members of a management team;
-has appointed corporate legal and financial advisors;
-has registered PVAXX  Corporation in Dubai, United Arab Emirates;

<PAGE>  3

Next 12 Months of Operations

(i) We intend to appoint a global distributor during the 1st quarter of
2001. When this has been achieved, we intend to ship production quantities
to customers (small quantities of PVAXX(R) are being shipped to various
potential customers for evaluation.  We anticipate that this will continue).
Currently, management anticipates average selling prices will be $1,200 per
ton for non-pharmaceutical grade and $6,000 per ton for pharmaceutical grade.
Should the company need additional financing prior to achieving greater
levels of sales, the President and majority shareholder may contribute
additional capital to the Company, or the Company may decide to raise capital
through the sale of equity.  The Company will have the ability to increase its
production capacity by two tons per hour.  Presently, the Company has the
ability to produce one ton per hour at its research facility located at
Kemble Business Park, Nr Malmesbury, Wiltshire, UK.;

(ii) We have completed the necessary product research and development, and
have sufficient manufacturing capacity, to supply samples and product during
the next 12 months. Small quantities of PVAXX polymers are already being
shipped in pellet form in 50 Kilo drums to various potential customers.
These shipments are purchased by the potential customer at market prices, but
are primarily used by the buyers to evaluate the functionality and durability of
PVAXX(R).  The Company also makes a sample of the product that the potential
customer will ultimately manufacture using PVAXX(R) and provides the sample
along with the PVAXX(R) polymer shipment. Prospective customers are responsible
to complete their own trials and tests to determine whether PVAXX(R) will be
suitable for production of their products.  If suitable, PVAXX(R) may be used
to enable the customer to produce products such as film, sheet, wrapping and
packaging materials, fibers and mouldings with no toxic effects on the
environment at an affordable cost;


(iii) We anticipate establishing an additional production facility in Dubai,
United Arab Emirates that will have the ability to produce an additional two
tons per hour of PVAXX(R).  The purchase and/or lease of significant equipment
in connection with this facility is fully factored into the production of two
tons per hour; and

(iv) We expect to hire an additional 6 employees for the production facility
in Dubai. Also to expand the management by 2 additional hirings.

We anticipate a proportion of the initial sales to customers will be to the
Italian market, where new legislation to ban a number of plastic applications
is currently in the implementation phase. A development partner in each market
sector (i.e. pharmaceuticals, agriculture, etc.) has been identified who will
eventually receive the first deliveries of PVAXX(R).  The pharmaceutical
sector is being developed over the mid-term, and offers higher-margin
opportunities.

<PAGE>  4

The first phase in the global commercialization of PVAXX  is currently
underway, with the approval to design and construct a new, state-of-the-art
production plant in Dubai.  This unit is being designed to produce PVAXX(R).
PVAXX(R) will be produced in pellet form, to allow easy use by
manufacturing customers, utilizing their existing plant and production
equipment.

Year 2001

The Company anticipates accomplishing the following during the calendar year
2001:

-will a achieve ISO 9002 Accreditation for the United Kingdom research and
 development unit;
-plans to construct and commission 100,000 MT manufacturing plant in Dubai,
 UAE;
-plans to supply first customers;
-plans to commence marketing program; and
-plans to supply 17,000 MT of product.

Year 2002

The Company plans to accomplish the following during the calendar year 2002:
-will achieve ISO 9002 Accreditation for the Dubai plant;
-will increase supply to 200,000 MT

Year 2003

The Company plans to accomplish the following during the calendar year 2003:
-will increase supply to 400,000 MT

Liquidity and Capital Resources

The Company remains in the development stage and, since inception, has
experienced no significant change in liquidity or capital resources or
stockholder's equity.  The Company's balance sheet as of December 31, 2000,
reflects a current asset value of $406,336, and a total asset value of
$1,084,406 in the form of cash and capitalized organizational costs.

The Company is hereby registering for the sale of equity in connection with
the sale of 1,200,000 shares at approximately $10.00/share. The Company does
not have any underwriting commitments for such sale of equity and cannot
provide assurances that it will raise significant proceeds from this offering
and may receive no or nominal proceeds, significantly restricting the
Company's activities and plan of operations.

<PAGE>  5

Notwithstanding the steps taken by us to raise additional capital, our
immediate cash requirements are significant. We cannot assure you that we
will be able to successfully realize cash flow from operations or that such
cash flow will be sufficient. We believe that our existing and anticipated
capital resources will enable us to fund our planned operations through Fiscal
2001.  In addition, our annual and quarterly operating results may be
affected by a number of factors, including the following:

     -    our ability to manage inventories, shortages of components or
          labor;
     -    the degree of automation used in the assembly process;
     -    fluctuations in material costs and the mix of material costs
          versus labor;
     -    manufacturing and overhead costs;
     -    price competition;
     -    the inability to pass on excess costs to customers;
     -    the timing of expenditures in anticipation of increased sales; and
     -    customer product delivery requirements.

Any one of these factors, or a combination thereof, could adversely affect
us.

The Company believes that obtaining $1,000,000 of net proceeds from this
offering will permit it to continue meeting its working capital obligations
and fund the further development of its business for at least the next 12
months.  There can be no assurance that any additional financing will be
available to the Company on acceptable terms, or at all. If adequate funds
are not available, the Company may be required to delay, scale back or
eliminate its research, engineering and development or manufacturing programs
or obtain funds through arrangements with partners or others that may require
the Company to relinquish rights to certain of its technologies or potential
products or other assets. Accordingly, the inability to obtain such
financing could have a material adverse effect on the Company's business,
financial condition and results of operations.


Evolving Industry Standards; Rapid Technological Changes

The Company's success in its business will depend in part upon its continued
ability to enhance its existing products, to introduce new products quickly
and cost effectively to meet evolving customer needs, to achieve market
acceptance for new product offerings and to respond to emerging industry
standards and other technological changes. There can be no assurance that the
Company will be able to respond effectively to technological changes or new
industry standards.  Moreover, there can be no assurance that competitors of
the Company will not develop competitive products, or that any such
competitive products will not have an adverse effect upon the Company's
operating results.  There can also be no assurance that the Company will be
successful in refining, enhancing and developing its operating strategies
and products going forward, that the costs associated with refining, enhancing
and developing such strategies and products will not increase significantly
in future periods or that the Company's existing technology will not become
obsolete as a result of ongoing technological developments in the
marketplace.

<PAGE>  6

Volatility of Stock Price

The Company believes factors such as the Company's liquidity and financial
resources, quarter to quarter and year-to-year variations in financial
results could cause the market price of the Company's common stock to
fluctuate substantially. Any adverse announcement with respect to such
matters or any shortfall in revenue or earnings from levels expected by
management could have an immediate and material adverse effect on the trading
price of the Company's common stock in any given period. As a result, the
market for the Company's common stock may experience material adverse price
and volume fluctuations and an investment in the Company's common stock is
not suitable for any investor who is unwilling to assume the risk associated
with any such price and volume fluctuations.

Sufficiency of Cash Flows

The Company believes that current cash balances and any cash generated from
operations and from available debt or equity financing will be sufficient to
meet its cash needs for working capital and capital expenditures for at least
the next twelve months provided at least $1,000,000 is raised in this offering.
Thereafter, if cash generated from operations is insufficient to satisfy
the Company's liquidity requirements, management may seek to sell additional
equity or obtain credit facilities.  The sale of additional equity could
result in additional dilution to the Company's shareholders.

Results of Operations

Limited revenues of $2877 were received by the Company through December 31,
2000.

Income Taxes

The Company accounts for income taxes in accordance with Statement of
Financial Accounting Standards No. 109, "Accounting for Income Taxes" issued
by the Financial Accounting Standards Board, under which deferred tax assets
and liabilities are provided on differences between the carrying amounts for
financial reporting and the tax basis of assets and liabilities for
income tax purposes using the enacted tax rates.  Under SFAS 109, deferred
tax assets may be recognized for temporary differences that will result in
deductible amounts in future periods. A valuation allowance is recognized if
on the weight of available evidence it is more likely than not that some
portion or the entire deferred tax asset will not be realized.


                          PART II  OTHER INFORMATION

ITEM 1.  Legal Proceedings

          Neither the Registrant nor any of its affiliates are a
          party, nor is any of their property subject, to material
          pending legal proceedings or material proceedings known
          to be contemplated by governmental authorities.


ITEM 2.  Changes in Securities

          None


ITEM 3.  Defaults Upon Senior Securities

          None


ITEM 4.  Submission of Matters to a Vote of Security Holders

          None

ITEM 5.  Other Information

          None

ITEM 6.  Exhibits and Reports on Form 8 K

         a.  Exhibits

             Exhibit 27. Financial Data Schedule

         b.  Reports on Form 8 K

             None


<PAGE>  17

INDEX TO EXHIBITS

<TABLE>
<CAPTION>

EXHIBIT      NO      DESCRIPTION

<S>          <C>     <C>


#            3.1     Articles of Incorporation of the Registrant, as amended;

#            3.2     Bylaws of the Registrant;

#            4.1     Instruments Defining Rights of Security Holders/Minutes
                     of Annual/Special Meetings of the Registrant;

#           10.1     Issuance of Restricted Shares from Authorized Shares

#           23.1     Consent of Mark T. Thatcher, P.C.;

x           27       Financial Data Schedule

x           99.1     Safe Harbor Compliance Statement

_______________________
x     Filed herewith.

#     Incorporated by reference from the Registrant's Amendment No. 2 to the
      Registration Statement filed on Form 10-SB on or about May 14, 1999.


                                   SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                           PVAXX CORPORATION


                                           /s/ Nadeau & Simmons, P.C.

DATE: February 15, 2001                    By: NADEAU & SIMMONS, P.C.
                                           Title: Filing Agent


</TABLE>